Research progress on molecular markers of immunosenescence in tumor development and immune checkpoint inhibitor therapy
10.3760/cma.j.cn114452-20240903-00486
- VernacularTitle:免疫衰老分子标志在肿瘤发生发展和免疫检查点抑制剂治疗中的研究进展
- Author:
Wendi LI
1
;
Lin XIAO
1
;
Wei CUI
1
Author Information
1. 国家癌症中心/国家肿瘤临床医学研究中心/中国医学科学院北京协和医学院肿瘤医院检验科，北京 100021
- Publication Type:Journal Article
- Keywords:
Immunnity;
Senescence;
Molecular markers;
Tumor;
Immune checkpoint inhibitor
- From:
Chinese Journal of Laboratory Medicine
2024;47(12):1487-1492
- CountryChina
- Language:Chinese
-
Abstract:
Immune checkpoint inhibitors (ICI) have brought breakthrough advancements to cancer therapy.However, the relatively low treatment response rate remains a significant challenge, highlighting the urgent need for effective laboratory biomarkers to monitor immunotherapy. Immunosenescence promotes tumor initiation and progression by reducing the immune surveillance capability of the body and plays a critical role in tumor progression and immunotherapy. With the application of techniques such as flow cytometry, multi-omics analysis, and single-cell technology, the detection of immunosenescence molecular markers has made significant progress in tumor risk assessment, prognosis prediction, and ICI efficacy monitoring.
